Shattuck Labs Announces Participation in Upcoming March Conferences
AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in March 2024.*Presentation Details*
Conference: TD Cowen 44th Annual Health Care Conference
Format: Panel Discussion and 1x1 Meetings
Panel Topic: Novel IO Corporate Panel Discussion
· Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
· Date: March 4, 2024
· Time: 10:30-11:30 a.m. ETConference: Leerink Partners Global Biopharma Conference 2024
Format: 1x1 Meetings
Dates: March 11-12, 2024
Conference: Citi's Biotech C-Suite Fireside Chat Series
Format: Fireside chat with covering analyst Yigal Nochomovitz, Ph.D.
· Presenters: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, M.B.A., Shattuck’s Chief Financial Officer
· Date: March 20, 2024
· Time: 11:00 a.m. ETA live webcast of the presentations will be available on the Investors section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.
*About Shattuck Labs, Inc.*
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, (“ARC®”), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
*Investor & Media Contact: *
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com